ASX:TLXBiotechs
A Look At Telix Pharmaceuticals’ Valuation As TLX101-Tx Glioblastoma Study Hits Key Safety Milestone
Telix Pharmaceuticals (ASX:TLX) has reached a key clinical milestone by completing enrolment in its Phase 1 IPAX-2 study of investigational radiopharmaceutical TLX101-Tx for newly diagnosed glioblastoma, with no dose-limiting toxicities reported at the highest doses tested.
See our latest analysis for Telix Pharmaceuticals.
Despite the positive glioblastoma update and new prostate cancer imaging collaborations, Telix Pharmaceuticals' share price is down 11.21% over the past month but up 43.8%...